Home > Insider Trading > Filing (0001192482-21-000212)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1267565	Collegium Pharmaceutical Inc	COLL	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1443841	Joseph Ciaffoni	C/O Collegium Pharmaceutical, Inc. 100 Technology Center Drive Stoughton MA 02072	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-03-01	48,616	$8.22	343,075	No	4	M	Direct
Common Stock	Disposition	2021-03-01	54,959	$22.56	288,116	No	4	S	Direct
Common Stock	Disposition	2021-03-01	9,809	$23.30	278,307	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Purchase)	Disposition	2021-03-01	48,616	$0.00	48,616	$8.22

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
16,205		2027-05-31	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2020.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.01 to $22.98, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) and (3).
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.00 to $23.54, inclusive.
48,616 shares under the option are exercisable. The option, initially representing a right to purchase a total of 259,283 shares, vests and becomes exercisable over a four-year period commencing on May 31, 2017. Twenty-five percent (25%) of the option vested and became exercisable on May 31, 2018 and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) at the end of each quarterly period over the remaining three years of the four-year period, subject to the reporting person's continued service with the Issuer.